Integrative approach to diagnosis and subsequent successful therapy of refractory follicular lymphoma using obinutuzumab in combination with bendamustine. Clinical observation-Reference-Cited by-同舟云学术

Integrative approach to diagnosis and subsequent successful therapy of refractory follicular lymphoma using obinutuzumab in combination with bendamustine. Clinical observation

Published:2023-05-22 Issue:2 Volume:3 Page:47-55
ISSN:2782-6171
Container-title:MD-Onco
language:
Short-container-title:jour

Author:

Zeynalova P. A.¹^ORCID,Ryabukhina Yu. E.²^ORCID,Abbasbeyli F. M.²^ORCID,Timofeeva O. L.²^ORCID,Allakhverdieva G. F.²^ORCID,Abramov D. S.³^ORCID,Valiev T. T.⁴^ORCID

Affiliation:

1. Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

2. Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

3. Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia

4. I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Abstract

In the presented observation, a female patient with diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma (advanced stages) received R-ABVD regimen therapy. Return of clinical symptoms observed at the onset of the disease, as well as renewed growth of the lymph nodes after 4th therapy cycle showed refractory disease. Considering the results of earlier studies, generally showing high effectiveness of primary treatment of patients with nodular lymphocyte-predominant Hodgkin lymphoma, reevaluation of immunomorphological type of lymphoproliferative disease was performed. After change of diagnosis to grade 3A follicular lymphoma, therapy was changed to obinutuzumab in combination with bendamustine leading to fast positive antitumor effect.

Publisher

Publishing House ABV Press

Reference25 articles.

1. Matasar M.J., Luminari S., Barr P.M. et al. Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs. Oncologist 2019;24(11):e1236–e50. DOI: 10.1634/theoncologist.2019-0138

2. Ott G., Katzenberger T., Lohr A. et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002;99(10):3806–12. DOI: 10.1182/blood.v99.10.3806

3. Hiddemann W., Kneba M., Dreyling M. et al. Frontline therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2005;106(12):3725–32. DOI: 10.1182/blood-2005-01-0016

4. Marcus R., Imrie K., Solal-Celigny P. et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisolone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26(28):4579–86. DOI: 10.1200/JCO.2007.13.5376

5. Herold M., Haas A., Srock S. et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25(15):1986–92. DOI: 10.1200/JCO.2006.06.4618